$3.38 Valuation | $0.60c Current SP | Fully Funded Phase 3 with First Patient in Coming Months, page-95

@ Grivarta - here is another way to think about the value on offer here vis-a-vis the number of patients required to justify the current market cap. If they can get just 1,750 prescriptions per year at (US$ 15,000 per year) at the suggested 70pct gross margins then annual gross profit will equal the current market cap.

With respect to your point about diuretics, these have been studied extensively over the years and they are sometimes prescribed as a symptomatic treatment, however their efficacy is marginal at best.

With respect to the cash required to pay for the treatments as I am sure you are aware, initially, we are just going for European approval, all of the European health services are socialised. The economic benefit to these systems of the drug would be very large. Here is a recent paper looking at the cost of community care vs bariatric surgery for IIH treatment in the UK, you will not that Prof Sinclair is one of the authors. https://www.sciencedirect.com/science/article/pii/S1550728921001556

We have covered before on this board, the use of bariatric surgery as an alternative treatment and to cut a long story short, we determined that the use of Presendin would be complementary and will likely be prescribed for a total period of @4 years, both before and for a period after bariatric surgery. In addition we determined that there are likely to be a number of patients (10% to 15%) who would not be suitable for bariatric surgery or where the surgery did not result in a reduction of ICP. Last point is that the incidence of IIH is rising both in the developed world but also in the developing world> India for example is on the cusp of a huge rise in the incidence of IIH from almost none 20 years ago there have been numerous papers published recently looking at this.